Meeting
2023 ASCO Annual Meeting
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in CheckMate 238.
Authors
Mahrukh M. Syeda
New York University School of Medicine, New York, NY
Mahrukh M. Syeda , Jennifer M Wiggins , Josephine Alegun , Saim Ali , Hao Tang , Sheen Wang , Kao-Tai Tsai , Keyur Desai , Sonia Dolfi , Daniel J. Tenney , Paolo Antonio Ascierto , James Larkin , Michele Del Vecchio , Jeffrey S. Weber , David Polsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02388906
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9577)
DOI
10.1200/JCO.2023.41.16_suppl.9577
Abstract #
9577
Poster Bd #
340
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.
First Author: James Larkin
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
First Author: Robert R. McWilliams
Poster
2013 ASCO Annual Meeting
NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM).
First Author: Douglas Buckner Johnson
Poster
2022 ASCO Annual Meeting
Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
First Author: F. Stephen Hodi